Leading UK cardiologist advises Provexis as novel “heart healthy” drink enters final stage of development

Professor David Webb, Leader of the Centre for Cardiovascular Science at the University of Edinburgh, United Kingdom, has joined Provexis Limited on their Scientific Advisory Board.

UK-based Provexis has developed CardioFlow®, a novel extract from tomato which has been shown to have a beneficial effect in reducing the tendency for excessive blood clotting, which in some circumstances can lead to heart attacks, stroke and deep vein thrombosis.

The extract, which has now been added to orange juice in order to create a mainstream “hearthealthy” drink for the adult population, is just about to enter final human trials prior to a launch in early 2004.

Dr Stephen Franklin, Chief Executive of Provexis, said:

“Many people are familiar with the idea of taking aspirin to reduce the tendency for the blood to clot.

The great advantage of CardioFlow® is that it is a natural fruit-derived extract that can be added to products like orange juice to provide real proven health benefits without affecting the taste.” Professor Webb, who has over 300 peer-reviewed publications in the clinical cardiovascular field, will work closely with the management of Provexis to develop a second generation CardioFlow® specifically for patients diagnosed with cardiovascular disease.


Press enquiries contact Dr Stephen Franklin on 0161 226 7256 or 07710 348774.

CardioFlow® is a water soluble, concentrated, extract from tomato that contains no lycopene. There are multiple active compounds within the extract, most of which have been fully characterised, which inhibit blood platelet aggregation. Platelet aggregation plays an important part in cardiovascular disease and the formation of blood clots typically associated with heart attacks, stroke and deep vein thrombosis. Provexis Limited, founded in 1999, is a Manchester and Aberdeen-based (UK) bioscience company developing natural products with proven efficacy for application in the functional food and medical food industries (www.provexis.com).

Provexis is commercialising new technology invented at the Rowett Research Institute in Aberdeen (www.Rowett.ac.uk) and it was recently funded by the Rising Stars Growth Fund, a new North West of England regional technology fund.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.